FDA approves rivanetin as the first-line treatment for lung cancer.

Published Date: 08 Mar 2024

For NSCLCs with EGFR exon 20 insertion mutations, a bispecific medication receives complete approval.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Base-edited T-cell therapy offers additional hope for treating resistant leukemia.

2.

Hybrid imaging test combines antibody and radioisotope for early lung cancer detection

3.

Maintenance Rituximab Improves Survival in Elderly MRD-Negative MCL Patients.

4.

Using MRD Status to Deescalate Multiple Myeloma Therapy

5.

Sydney researchers identify new tools to improve cancer diagnosis and treatment.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot